Evaluating the effects of an interdisciplinary practice model with pharmacist collaboration on HIV patient co-morbidities

AIDS Patient Care and STDs

Volumn 29, Issue 8, 2015, Pages 445-453

  Cope, Rebecca ^a   Berkowitz, Leonard ^b   Arcebido, Rebecca ^b   Yeh, Jun Yen ^c   Trustman, Nathan ^c   Cha, Agnes ^c  

^a TOURO COLLEGE   (United States)

^b BROOKLYN HOSPITAL CENTER   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLIPIDEMIA; HYPERTENSION; INTERDISCIPLINARY PRACTICE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHARMACIST; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SMOKING; VIRUS LOAD; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HIV INFECTIONS; PATIENT CARE; PHARMACY; PHYSICIAN; PRIMARY HEALTH CARE; PROCEDURES; PROFESSIONAL STANDARD; PROGRAM EVALUATION; PUBLIC RELATIONS;

ADULT; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; INTERPROFESSIONAL RELATIONS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE TEAM; PHARMACEUTICAL SERVICES; PHYSICIANS; PRIMARY HEALTH CARE; PROFESSIONAL ROLE; PROGRAM EVALUATION; RETROSPECTIVE STUDIES;

EID: 84938347104     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2015.0018     Document Type: Article

References (62)

1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: Increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8: e81355.
2. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014; 28: 1193-1202.
3. May MT, Ingle SM. Life expectancy of HIV-positive adults: A review. Sec Health 2011; 8: 526-533.
4. CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 U.S. dependent areas-2011. HIV Surveillance Supplemental Report 2013; 18.
5. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 U.S. dependent areas: 2010. HIV Surveillance Supplemental Report 2012; 17. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ (Last accessed February 5, 2014.
6. Justice AC. HIV and aging: Time for a new paradigm. Curr HIV/AIDS Rep 2010; 7: 69-76.
7. Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med 2007; 23: 567-583.
8. May M, Gompels M, Sabin C. Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study. AIDS Society 2012; 15: Supp 4.
9. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-analysis. HIV Med 2012; 13: 453-468.
10. Glass TR, Ungsedhapand C, Wolbers M, et al. Swiss H. I. V. Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: The Swiss HIV Cohort Study. HIV Med 2006; 7: 404-410.
11. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. J Acquir Immune Defic Syndr 2002; 30: 471-477.
12. D. A. D. Study Group, Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: A multi-cohort collaboration. Lancet 2008; 371: 1417-1426.
13. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular disease from anti-retroviral therapy for HIV: A systematic review. PLoS One 2013; 8: e59551.
14. Goulet JL, Fultz SL, Rimland D. Aging and infectious diseases: Do patterns of co-morbidity vary by HIV status, age, and HIV severity?. Clin Infect Dis 2007; 45: 1593.
15. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
16. Schouten J, Wit F, Stolte I. Cross-sectional comparison of the prevalence of age-associated co-morbidities and their risk factors between HIV-infected and uninfected individuals: The AGEhIV Cohort Study. Clin Infect Dis 2014; 59: 1787-1797.
17. Centers for Disease Control and Prevention. Diagnosed HIV infection among adults and adolescents in metropolitan statistical areas-United States and Puerto Rico, 2011. HIV Surveillance Supplemental Report 2013; 18. Revised 2014. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/ (Last accessed March 11, 2015)
18. Chu C, Umanski G, Blank A, et al. Co-morbidity related treatment outcomes among HIV-infected adults in the Bronx, NY. J Urban Health 2011; 88: 507-516.
19. Tseng A, Foisy M, Hughes CA, et al. Role of the pharmacist in caring for patients with HIV/AIDS: Clinical practice guidelines. Can J Hosp Pharm 2012; 65: 125.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http:/aids info.nih.gov/contentfiles/lvguidelines/adultandadolescentgl .pdf (Last accessed June 24, 2014)
21. Cohen H. Pharmacists and collaborative drug therapy management in New York State. J Pharma Pract 2011; 24: 582.
22. Odum L, Whaley-Connell A. The role of team-based care involving pharmacists to improve cardiovascular and renal outcomes. Cardiorenal Med 2012; 2: 243.
23. Crisholm-Burnes MA, Kim Lee J, Spivey CA, et al. US pharmacists effect as team members on patient care: Systematic review and meta-analyses. Med Care 2010; 48: 923-933.
24. Ip E, Shah B, Yu J, et al. Enhancing diabetes care by adding a pharmacist to the primary care team. Am J Health-Syst Pharm 2013; 70: 877.
25. Saberi P, Dong B, Johnson M, et al. The impact of HIV clinical pharmacists on HIV treatment outcomes: A systematic review. Patient Prefer Adherence 2012; 6: 297.
26. March K, Mak M, Louie S. Effects of pharmacists interventions on patient outcomes in an HIV primary care clinic. Am J Health-Syst Pharm 2007; 64: 2574.
27. Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE 2012; 7: e31591.
28. Murphy P, Cocohoba J, Tang A, et al. Impact of HIVspecialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDs 2012; 26: 526-531.
29. Calderon Y, Cowan E, Rhee JY, Brusalis C, Leider J. Counselor-based rapid HIV testing in community pharmacies. AIDS Patient Care STDs 2013; 27: 467-473.
30. Vachirasudlekha B, Cha A, Berkowitz L, Shah B. Interdisciplinary HIV care-Patient perceptions. Int J Health Care Qual Assur 2014; 27: 405-413.
31. Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Comorbidities in persons infected with HIV: Increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDs 2013; 27: 5-16.
32. Zavascki AP, Fuchs SC. The need for reappraisal of AIDS score weight of Charlson co-morbidity index. J Clin Epidemiol 2007; 60: 867-868.
33. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560.
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486.
35. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239.
36. Sacco R, Adams R, Albers G, et al. AHA/ASA Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006; 37: 577.
37. Smith S, Benjamin E, Bonow R, et al. AHA/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 Update. Circulation 2011; 124: 2458.
38. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, et al. Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clin Infect Dis 2000; 31: 808-812.
39. Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015; 29: 221-229.
40. Clifford GM, Lise M, Franceschi S, et al. Lung cancer in the Swiss HIV Cohort Study: Role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012; 106: 447-452.
41. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2889-2934.
42. James P, Oparil S, Carter B, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA 2014; 311: 507.
43. Conover CJ, Weaver M, Arno P, et al. Insurance coverage among people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders. J Health Care Poor Underserved 2010; 21: 1006-1030.
44. Aspirin for the Prevention of Cardiovascular Disease, Topic Page. U.S. Preventive Services Task Force. Available at: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasmi .htm (Last accessed June 24, 2014)
45. Nahvi S, Cooperman MA. Review: The need for smoking cessation among HIV-positive smokers. AIDS Educ Prev 2009; 21: 14-27.
46. Matthews AK, Conrad M, Kuhns L, Vargas M, King AC. Project Exhale: Preliminary evaluation of a tailored smoking cessation treatment for HIV-positive African American smokers. AIDS Patient Care STDs 2013; 27: 22-32.
47. Wewers ME, Neidig JL, Kihm KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. J Assoc Nurses AIDS Care 2000; 11: 37-44.
48. Vidrine DJ, Arduino RC, Lazev AB, Gritz ER. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS 2006; 20: 253-260.
49. Grover KW, Gonzalez A, Zvolensky MJ. HIV symptom distress and smoking outcome expectancies among HIV+ smokers: A pilot test. AIDS Patient Care STDs 2013; 27: 17-21.
50. Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: An update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Resp 2012; 14: 67-82.
51. Castillo E, Palepu A, Beardsell A, et al. Outpatient pharmacy care and HIV viral load response among patients on HAART. AIDS Care 2004; 16: 446-457.
52. Rathbun RC, Farmer KC, Stephens JR, et al. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: A prospective, randomized, controlled pilot study. Clin Ther 2005; 27: 199-209.
53. Horberg MA, Hurley LB, Silverberg MJ, et al. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44: 531-539.
54. Ma A, Chen DM, Chau FM, et al. Improving adherence and clinical outcomes through an HIV pharmacists interventions. AIDS Care 2010; 22: 1189-1194.
55. Henderson KC, Hindman J, Johnson SC, et al. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. AIDS Patient Care STDs 2011; 25: 221-228.
56. Arcebido R, Cha A, Rubin R. Pharmacist interventions through collaborative drug therapy management in an interdisciplinary HIV cClinic. MAD-ID Annual Meeting, Orlando, FL, May 10, 2013.
57. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy 2001; 21: 1337-1344.
58. Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM. Statin cost-effectiveness comparisons using real-world effectiveness data: Formulary implications. Value Health 2008; 11: 1061-1069.
59. Franklin B, Zarland M, Thomas J, et al. Pharmacoeconomic analysis of the Diabetes Initiative Program: A pharmacistphysician collaborative care model. Ann Pharmacother 2013; 47: 1627-1634.
60. Cantor B, Deshmukh A, Stancic Luca N, et al. Costeffectiveness analysis of smoking-cessation counseling training for physicians and pharmacists. Addictive Behav 2015; 45: 79-86.
61. Shepler BM. Cost savings associated with pharmacy student interventions during APPEs. Am J Pharmaceut Edu 2014; 78: Article 71.
62. Measuring Price Change for Medical Care in the CPI. U.S. Bureau of Labor Statistics. Updated 12 Apr 2010. Available at: http://www.bls.gov/cpi/cpifact4.htm (Last accessed April 10, 2015)